Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Fecal Matrix Metalloproteinase-9 Measurement for Optimizing Detection of Disease Activity in Inflammatory Bowel Disease.

Kreijne JE, van der Giessen J, Verhaar AP, Peppelenbosch MP, de Vries AC, van der Woude CJ, Fuhler GM.

J Clin Gastroenterol. 2019 May/Jun;53(5):395-397. doi: 10.1097/MCG.0000000000000952. No abstract available.

PMID:
29256991
2.

Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype.

Meijer MJ, Mieremet-Ooms MA, van der Zon AM, van Duijn W, van Hogezand RA, Sier CF, Hommes DW, Lamers CB, Verspaget HW.

Dig Liver Dis. 2007 Aug;39(8):733-9. Epub 2007 Jun 29.

PMID:
17602907
3.

The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases.

Farkas K, Saródi Z, Bálint A, Földesi I, Tiszlavicz L, Szűcs M, Nyári T, Tajti J, Nagy F, Szepes Z, Bor R, Annaházi A, Róka R, Molnár T.

J Crohns Colitis. 2015 Mar;9(3):231-7. doi: 10.1093/ecco-jcc/jjv005. Epub 2015 Jan 12.

PMID:
25585596
4.

Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases.

Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, van Duijn W, van den Berg M, van Hogezand RA, Lamers CB, Verspaget HW.

Dig Liver Dis. 2005 Aug;37(8):584-92.

PMID:
15869913
5.

FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.

Kotze LM, Nisihara RM, Marion SB, Cavassani MF, Kotze PG.

Arq Gastroenterol. 2015 Jan-Mar;52(1):50-4. doi: 10.1590/S0004-28032015000100011.

6.

Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?

Di Ruscio M, Vernia F, Ciccone A, Frieri G, Latella G.

Inflamm Bowel Dis. 2017 Dec 19;24(1):78-92. doi: 10.1093/ibd/izx011. Review.

PMID:
29272479
7.

EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.

Faubion WA Jr, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME.

Am J Gastroenterol. 2013 Dec;108(12):1891-900. doi: 10.1038/ajg.2013.354. Epub 2013 Oct 15. Erratum in: Am J Gastroenterol. 2014 May;109(5):780.

PMID:
24126633
8.

Accuracy of four fecal assays in the diagnosis of colitis.

Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F.

Dis Colon Rectum. 2007 Oct;50(10):1697-706.

PMID:
17762964
9.

Relationship between fecal lactoferrin and inflammatory bowel disease.

Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ.

Scand J Gastroenterol. 2007 Dec;42(12):1440-4.

PMID:
17852860
10.

Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease.

Kolho KL, Sipponen T, Valtonen E, Savilahti E.

Int J Colorectal Dis. 2014 Jan;29(1):43-50.

PMID:
24077667
11.

The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.

Kwapisz L, Gregor J, Chande N, Yan B, Ponich T, Mosli M.

Scand J Gastroenterol. 2017 Aug;52(8):846-850. doi: 10.1080/00365521.2017.1315740. Epub 2017 Apr 20.

PMID:
28423962
12.

Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.

Mäkitalo L, Rintamäki H, Tervahartiala T, Sorsa T, Kolho KL.

Scand J Gastroenterol. 2012 Jul;47(7):785-94. doi: 10.3109/00365521.2012.677954. Epub 2012 Apr 23.

PMID:
22519363
13.

Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease.

Jang HW, Kim HS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH.

Intest Res. 2016 Oct;14(4):305-313. Epub 2016 Oct 17.

14.

Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Vieira A, Fang CB, Rolim EG, Klug WA, Steinwurz F, Rossini LG, Candelária PA.

BMC Res Notes. 2009 Oct 29;2:221. doi: 10.1186/1756-0500-2-221.

15.

Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.

Kostakis ID, Cholidou KG, Vaiopoulos AG, Vlachos IS, Perrea D, Vaos G.

Dig Dis Sci. 2013 Feb;58(2):309-19. doi: 10.1007/s10620-012-2347-5. Epub 2012 Aug 17. Review.

PMID:
22899243
16.

Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.

Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T.

Int J Mol Med. 2018 Jan;41(1):107-118. doi: 10.3892/ijmm.2017.3244. Epub 2017 Nov 7.

17.

Fecal lysozyme in assessment of disease activity in inflammatory bowel disease.

van der Sluys Veer A, Brouwer J, Biemond I, Bohbouth GE, Verspaget HW, Lamers CB.

Dig Dis Sci. 1998 Mar;43(3):590-5.

PMID:
9539656
18.

Matrix metalloproteinase-9 inhibition reduces inflammation and improves motility in murine models of postoperative ileus.

Moore BA, Manthey CL, Johnson DL, Bauer AJ.

Gastroenterology. 2011 Oct;141(4):1283-92, 1292.e1-4. doi: 10.1053/j.gastro.2011.06.035. Epub 2011 Jun 22.

19.

Role of MMP-2 and MMP-9 and their natural inhibitors in liver fibrosis, chronic pancreatitis and non-specific inflammatory bowel diseases.

Kurzepa J, Mądro A, Czechowska G, Kurzepa J, Celiński K, Kazmierak W, Slomka M.

Hepatobiliary Pancreat Dis Int. 2014 Dec;13(6):570-9. Review.

PMID:
25475858
20.

Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease.

Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE.

J Pediatr Gastroenterol Nutr. 2001 Jul;33(1):14-22.

PMID:
11479402

Supplemental Content

Support Center